Masculinizing hormone therapy, also known as transmasculine hormone therapy, or female-to-male (or FTM) hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. It is a common type of transgender hormone therapy (another being feminizing hormone therapy), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect.
The purpose of this form of therapy is to cause the development of the secondary sex characteristics of the desired sex, such as voice deepening and a masculine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse. The medications used for FTM therapy include, mainly, androgens (namely testosterone) and GnRH analogues.
While the therapy cannot undo the effects of a person's first puberty, developing secondary sex characteristics associated with a different sex can relieve some or all of the distress and discomfort associated with gender dysphoria, and can help the person to "pass" or be seen as their gender identity. Introducing exogenous hormones into the body impacts it at every level and many patients report changes in energy levels, mood, appetite, etc. The goal of the therapy, and indeed all somatic treatments, is to provide patients with a more satisfying body that is more congruent with their gender identity.
Masculinizing hormone therapy has been shown to likely reduce the distress and discomfort associated with gender dysphoria.
To produce masculinization and/or defeminization in transgender men and genderqueer individuals.
To produce masculinization and/or defeminization in intersex people.
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
vignette|Seringue, parfois utilisée pour l'hormonosubstitution dans le cadre d'injections intramusculaires. L’hormonosubstitution, thérapie hormonale substitutive ou encore hormonothérapie est un traitement hormonal médical traitement médical destiné à entraîner une féminisation ou une masculinisation du corps d'une personne trans, en influençant l'aspect des caractères sexuels secondaires. Sa mise en place se fait généralement sous la surveillance d'un professionnel de santé.
La testostérone est un médicament et une hormone stéroïde naturelle. Elle est utilisée pour traiter l' hypogonadisme masculin, la dysphorie de genre et certains types de cancer du sein. Elle peut également être utilisé pour augmenter la capacité athlétique sous forme de dopage .On ne sait pas exactement si l'utilisation de la testostérone pour remédier aux faibles niveaux dus au vieillissement est bénéfique ou nocive. La testostérone peut être utilisée sous forme de gel ou de patch à appliquer sur la peau, à injecter dans un muscle, à placer dans la joue ou à prendre par la bouche.
Feminizing hormone therapy, also known as transfeminine hormone therapy, is hormone therapy and sex reassignment therapy to change the secondary sex characteristics of transgender people from masculine or androgynous to feminine. It is a common type of transgender hormone therapy (another being masculinizing hormone therapy) and is used to treat transgender women and non-binary transfeminine individuals. Some, in particular intersex people but also some non-transgender people, take this form of therapy according to their personal needs and preferences.
Explore la transition entre les sexes, l'évaluation psychiatrique, l'hormonothérapie, les risques et les disparités dans les soins de santé transgenres dans le monde entier.
Background aims: Age-related macular degeneration (AMD) is the most common cause of blindness in elderly patients within developed countries, affecting more than 190 million worldwide. In AMD, the retinal pigment epithelial (RPE) cell layer progressively d ...
Elsevier Sci Ltd2024
,
Lobular carcinoma represent the most common special histological subtype of breast cancer, with the majority classed as hormone receptor positive. Rates of invasive lobular carcinoma in postmenopausal women have been seen to increase globally, while other ...
In phenylketonuria, absence or malfunction of the phenylalanine hydroxylase enzyme results in toxic accumulation of phenylalanine in the body. An injectable recombinant enzyme therapy was recently approved and has the potential to improve the quality of li ...